This week, MedDay Pharmaceuticals announced that the second pivotal Phase 3 trial (SPI2) of MD1003 (biotin), an investigational product for primary and secondary progressive MS has failed to meet its primary and secondary endpoints.
The Futureproofing Healthcare MS Index focuses on the treatment of MS across 30 European countries, with Ireland ranking in bottom third overall
A cognitive occupation-based programme for people with multiple sclerosis: A randomised controlled pilot trial to improve cognition and daily functioning for people with multiple sclerosis.
Bladder dysfunction and management strategies among people with Multiple sclerosis (MS): a qualitative study of people with MS perspectives
MS talks at the 2019 Annual Conference in Limerick
The European Commission is hosting a survey consultation on the current European Disability Strategy
The European Medicines Agency has issued a press release recommending that Gilenya (fingolimod) not be used during pregnancy or by women of child-baring age who are not using effective contraception.
New €3.9 million NUI Galway-led European consortium to train researchers in developing new treatments for Multiple Sclerosis
© 2010 - 2020 Multiple Sclerosis Society of Ireland